The Company's principal activity is to develop products for the treatment of cancer. The Company is developing novel, small molecule therapies that target the molecular mechanisms that cause cancer. The company's lead products are Nexavar (R), Sorafenib tablets, being developed with our collaborator, Bayer Pharmaceuticals Corporation. The Company also has a small molecule cell cycle inhibitor from collaboration with Pfizer advancing towards clinical development. By exploiting the genetic differences between cancer cells and normal cells, the Company is focused on changing the way cancer is treated by creating anticancer therapies aimed at avoiding damage to healthy tissue while destroying malignant cells.
Alacra Alerts:
Receive alerts on the latest reports on ONYX Pharmaceuticals, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
